ArticlePloS one2018
Trends in the seroprevalence of Helicobacter pylori infection and its putative eradication rate over 18 years in Korea: A cross-sectional nationwide multicenter study.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Preventable Cancers Caused by Infection in Korea From 2015 to 2030.Journal of Korean medical science · 2025Pooled it
- Population Attributable Fraction of Helicobacter pylori Infection-Related Gastric Cancer in Korea: A Meta-Analysis.Cancer research and treatment · 2021Pooled it
- Trial
- Occurrence of New Helicobacter pylori Infections in Healthy, Helicobacter pylori-Negative Adults: A Prospective Observational Study.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality.Journal of gastroenterology and hepatology · 2026Article
- Infection-driven cancers in Asia: implications from epidemiological transitions.The Lancet regional health. Western Pacific · 2026Review
- Sex-Specific Differences in Helicobacter pylori Eradication Outcomes: Treatment Success and Adverse Events in a Single Tertiary Center in South Korea.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Treatment of Helicobacter pylori Infection in Korea: An Evidence-Based Analysis of the Upcoming 2025 Guideline.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Spatio-temporal changes in clusters of gastric cancer incidence: The impact of nationwide cancer control programs in South Korea.PloS one · 2026Article
- Increased risk of early-onset gastric cancer among young adults age 20-49 years with diabetes: a nationwide cohort study.EClinicalMedicine · 2025Article
- Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Role of Serum Pepsinogen Tests in Detection of Gastric Atrophy, Intestinal Metaplasia, Gastric Adenoma, and Gastric Cancer in South Korea.Gut and liver · 2025Article
- The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study.JMIR research protocols · 2025Article
- National prevention programs and their effects on gastric cancer Incidence and mortality in East Asian countries.Cancer biology & medicine · 2025Article
- Nomogram Prediction for Gastric Cancer Development.Clinical and translational gastroenterology · 2025Article
- Epidemiological status of family-based Helicobacter pylori infection in Yunnan Province, China.BMC gastroenterology · 2025Article
- Differences in the Effect of Physical Activity on the Prevention of Gastric Cancer According to Sex.Journal of gastric cancer · 2025Article
- Assessing Serum Pepsinogen andCancers · 2025Article
- Peptic Ulcer Disease.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Epidemiology and socioeconomic correlates of gastric cancer in Asia: results from the GLOBOCAN 2020 data and projections from 2020 to 2040.Scientific reports · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aims of this study were to demonstrate the trends in seropositivity and the eradication therapy rate for Helicobacter pylori (H. pylori) over an 18-year period in an asymptomatic Korean population and to explore the factors associated with H. pylori seropositivity and its eradication therapy. In total, 23,770 subjects (aged 17-97 years) from a health examination center participated in this cross-sectional study from January 2016 to June 2017. Questionnaires that included questions about the participants' H. pylori eradication therapy history were collected, and anti-H. pylori IgG antibodies were measured. Among the eligible subjects, the seroprevalence of H. pylori infection was 41.5%. The H. pylori eradication therapy rate increased continuously from 2005 (13.9%) to 2011 (19.3%) and then increased again until the first half of 2017 (23.5%) (P < 0.001). After exclusion of subjects with a history of gastric surgery, gastric cancer, H. pylori eradication therapy, or gastric symptoms, H. pylori seropositivity was 43.9% in 16,885 subjects, which was significantly lower than the seropositivities in 1998 (66.9%), 2005 (59.6%), and 2011 (54.4%). The risk factors associated with H. pylori seropositivity according to multivariable analysis were male sex (odds ratio (OR) 1.34, 95% confidence interval (CI): 1.23-1.46), medium educational level (OR 1.17, 95% CI: 1.05-1.31), medium household income level (OR 1.10, 95% CI: 1.03-1.19), and age of 60-69 years (OR 8.78, 95% CI: 6.41-11.85). The observed downward trend in H. pylori seroprevalence and increase in H. pylori eradication over the 18-year period will affect upper gastrointestinal disorders in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.